Difference between revisions of "How I Treat"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
(186 intermediate revisions by 2 users not shown)
Line 3: Line 3:
 
[[#top|Back to Top]]
 
[[#top|Back to Top]]
 
</div>
 
</div>
−
The "How I Treat" series has been published by ''Blood'' for several decades and covers a wide variety of topics in malignant and classical hematology. While these articles are not considered to be formal guidelines, they are considered highly reputable sources of expert opinion. They cover topics ranging from commonly encountered hematologic conditions with a large evidence base, to very rare conditions with only case reports to guide treatment. The purpose of this page is to consolidate the links to all known published How I Treat articles.  
+
The "How I Treat" series has been published by ''Blood'' for several decades and covers a wide variety of topics in malignant and classical hematology. While these articles are not considered to be formal guidelines, they are considered highly reputable sources of expert opinion. They cover topics ranging from commonly encountered hematologic conditions with a large evidence base, to very rare conditions with only case reports to guide treatment. The purpose of this page is to consolidate the links to all known published How I Treat articles. While the vast majority of these are published in ''Blood'', there are a few exceptions.
  
−
'''In the first two sections (malignant hematology and classical hematology), articles are presented by condition, in reverse chronological order. In the third section, articles are gathered under "special considerations" such as pregnancy and hematologic disease. Given the rapid change in evidence in many areas of hematology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.'''
+
'''In the first two sections (malignant hematology and classical hematology), articles are presented by condition, in reverse chronological order. In the third section, articles are gathered under "special considerations" such as pregnancy and hematologic disease. The fourth section contains miscellaneous topics that do not easily fit into the above categories. Given the rapid change in evidence in many areas of hematology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.'''
−
 
 
−
''Note: this page is currently under construction.''
 
  
 
=Malignant hematology=
 
=Malignant hematology=
 +
==Acute leukemias==
 +
===Mixed-phenotype acute leukemia (MPAL)===
 +
*'''2015:''' Wolach & Stone. [https://doi.org/10.1182/blood-2014-10-551465 How I treat mixed-phenotype acute leukemia] [https://pubmed.ncbi.nlm.nih.gov/25605373/ PubMed]
 
==Myeloid neoplasms==
 
==Myeloid neoplasms==
 
===[[:Category:Acute lymphoblastic leukemias|Acute lymphoblastic leukemia (ALL)]]===
 
===[[:Category:Acute lymphoblastic leukemias|Acute lymphoblastic leukemia (ALL)]]===
Line 22: Line 23:
 
*'''2015:''' Curran & Stock. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4463735/ How I treat acute lymphoblastic leukemia in older adolescents and young adults] [https://pubmed.ncbi.nlm.nih.gov/25805810/ PubMed]
 
*'''2015:''' Curran & Stock. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4463735/ How I treat acute lymphoblastic leukemia in older adolescents and young adults] [https://pubmed.ncbi.nlm.nih.gov/25805810/ PubMed]
 
*'''2015:''' Frey & Luger. [https://doi.org/10.1182/blood-2014-09-551937 How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia] [https://pubmed.ncbi.nlm.nih.gov/25966988/ PubMed]
 
*'''2015:''' Frey & Luger. [https://doi.org/10.1182/blood-2014-09-551937 How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia] [https://pubmed.ncbi.nlm.nih.gov/25966988/ PubMed]
 +
*'''2015:''' Litzow & Ferrando. [https://doi.org/10.1182/blood-2014-10-551895 How I treat T-cell acute lymphoblastic leukemia in adults] [https://pubmed.ncbi.nlm.nih.gov/25966987/ PubMed]
 +
*'''2013:''' Gökbuget. [https://doi.org/10.1182/blood-2012-07-379016 How I treat older patients with ALL] [https://pubmed.ncbi.nlm.nih.gov/23673859/ PubMed]
 +
*'''2012:''' Locatelli et al. [https://doi.org/10.1182/blood-2012-02-265884 How I treat relapsed childhood acute lymphoblastic leukemia] [https://pubmed.ncbi.nlm.nih.gov/22896001/ PubMed]
 +
*'''2007:''' Rowe & Goldstone. [https://doi.org/10.1182/blood-2007-05-038950 How I treat acute lymphocytic leukemia in adults] [https://pubmed.ncbi.nlm.nih.gov/17596539/ PubMed]
  
 
===[[Acute myeloid leukemia|Acute myeloid leukemia (AML)]]===
 
===[[Acute myeloid leukemia|Acute myeloid leukemia (AML)]]===
 +
*'''2024:''' Thol et al. [https://doi.org/10.1182/blood.2023022481 How I treat refractory and relapsed acute myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/37944143/ PubMed]
 +
**'''2020:''' DeWolf & Tallman. [https://doi.org/10.1182/blood.2019001982 How I treat relapsed or refractory AML] [https://pubmed.ncbi.nlm.nih.gov/32518943/ PubMed]
 
*'''2023:''' Biederstädt & Rezvani. [https://doi.org/10.1182/blood.2021012411 How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy] [https://pubmed.ncbi.nlm.nih.gov/35512203/ PubMed]
 
*'''2023:''' Biederstädt & Rezvani. [https://doi.org/10.1182/blood.2021012411 How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy] [https://pubmed.ncbi.nlm.nih.gov/35512203/ PubMed]
 +
*'''2023:''' El Chaer et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10447497/ How I treat AML incorporating the updated classifications and guidelines] [https://pubmed.ncbi.nlm.nih.gov/36758209/ PubMed]
 
*'''2021:''' Falini et al. [https://doi.org/10.1182/blood.2020008211 How I diagnose and treat NPM1-mutated AML] [https://pubmed.ncbi.nlm.nih.gov/33171486/ PubMed]
 
*'''2021:''' Falini et al. [https://doi.org/10.1182/blood.2020008211 How I diagnose and treat NPM1-mutated AML] [https://pubmed.ncbi.nlm.nih.gov/33171486/ PubMed]
 
*'''2021:''' Rubnitz & Kaspers. [https://doi.org/10.1182/blood.2021011694 How I treat pediatric acute myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/34115839/ PubMed]
 
*'''2021:''' Rubnitz & Kaspers. [https://doi.org/10.1182/blood.2021011694 How I treat pediatric acute myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/34115839/ PubMed]
−
*'''2020:''' DeWolf & Tallman. [https://doi.org/10.1182/blood.2019001982 How I treat relapsed or refractory AML] [https://pubmed.ncbi.nlm.nih.gov/32518943/ PubMed]
 
 
*'''2020:''' DiNardo & Wei. [https://doi.org/10.1182/blood.2019001239 How I treat acute myeloid leukemia in the era of new drugs] [https://pubmed.ncbi.nlm.nih.gov/31765470/ PubMed]
 
*'''2020:''' DiNardo & Wei. [https://doi.org/10.1182/blood.2019001239 How I treat acute myeloid leukemia in the era of new drugs] [https://pubmed.ncbi.nlm.nih.gov/31765470/ PubMed]
 
*'''2016:''' Ofran et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524532/ How I treat acute myeloid leukemia presenting with preexisting comorbidities] [https://pubmed.ncbi.nlm.nih.gov/27235136/ PubMed]
 
*'''2016:''' Ofran et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524532/ How I treat acute myeloid leukemia presenting with preexisting comorbidities] [https://pubmed.ncbi.nlm.nih.gov/27235136/ PubMed]
 +
*'''2016:''' Peffault de Latour & Soulier. [https://doi.org/10.1182/blood-2016-01-583625 How I treat MDS and AML in Fanconi anemia] [https://pubmed.ncbi.nlm.nih.gov/27020090/ PubMed]
 +
*'''2016:''' Pratz & Levis. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5290983/ How I treat FLT3-mutated AML] [https://pubmed.ncbi.nlm.nih.gov/27872057/ PubMed]
 
*'''2015:''' Röllig & Ehninger. [http://www.bloodjournal.org/content/125/21/3246.long How I treat hyperleukocytosis in acute myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/25778528/ PubMed]
 
*'''2015:''' Röllig & Ehninger. [http://www.bloodjournal.org/content/125/21/3246.long How I treat hyperleukocytosis in acute myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/25778528/ PubMed]
 
*'''2014:''' Ossenkoppele & Löwenberg. [http://www.bloodjournal.org/content/125/5/767.long How I treat the older patient with acute myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/25515963/ PubMed]
 
*'''2014:''' Ossenkoppele & Löwenberg. [http://www.bloodjournal.org/content/125/5/767.long How I treat the older patient with acute myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/25515963/ PubMed]
 
*'''2011:''' Bakst et al. [https://doi.org/10.1182/blood-2011-04-347229 How I treat extramedullary acute myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/21795742/ PubMed]
 
*'''2011:''' Bakst et al. [https://doi.org/10.1182/blood-2011-04-347229 How I treat extramedullary acute myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/21795742/ PubMed]
 +
 +
===[[Acute promyelocytic leukemia|Acute promyelocytic leukemia (APL)]]===
 +
*'''2014:''' Sanz & Motesinos. [https://doi.org/10.1182/blood-2013-10-512640 How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia] [https://pubmed.ncbi.nlm.nih.gov/24627526/ PubMed]
 +
*'''2009:''' Tallman & Altman. [https://doi.org/10.1182/blood-2009-07-216457 How I treat acute promyelocytic leukemia] [https://pubmed.ncbi.nlm.nih.gov/19797519/ PubMed]
  
 
===[[Chronic myeloid leukemia|Chronic myeloid leukemia (CML)]]===
 
===[[Chronic myeloid leukemia|Chronic myeloid leukemia (CML)]]===
 
*'''2022:''' Berman. [https://doi.org/10.1182/blood.2021011722 How I treat chronic-phase chronic myelogenous leukemia]
 
*'''2022:''' Berman. [https://doi.org/10.1182/blood.2021011722 How I treat chronic-phase chronic myelogenous leukemia]
 
*'''2019:''' Hijiya & Suttorp. [http://www.bloodjournal.org/content/133/22/2374.long How I treat chronic myeloid leukemia in children and adolescents]
 
*'''2019:''' Hijiya & Suttorp. [http://www.bloodjournal.org/content/133/22/2374.long How I treat chronic myeloid leukemia in children and adolescents]
 +
*'''2016:''' Gotlib. [https://doi.org/10.1182/blood-2016-08-693630 How I treat atypical chronic myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/27899359/ PubMed]
 +
*'''2012:''' Cortes & Kantarjian. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4916560/ How I treat newly diagnosed chronic phase CML] [https://pubmed.ncbi.nlm.nih.gov/22613793/ PubMed]
 +
*'''2009:''' Radich. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3654782/ How I monitor residual disease in chronic myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/19661271/ PubMed]
  
 +
===[[Chronic myelomonocytic leukemia|Chronic myelomonocytic leukemia (CMML)]]===
 +
*'''2017:''' Solary & Itzykson. [https://doi.org/10.1182/blood-2017-04-736421 How I treat chronic myelomonocytic leukemia] [https://pubmed.ncbi.nlm.nih.gov/28572287/ PubMed]
 +
 +
===[[Hypereosinophilic syndrome|Hypereosinophilic syndrome (HES)]]===
 +
*'''2015:''' Klion. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4551360/ How I treat hypereosinophilic syndromes] [https://pubmed.ncbi.nlm.nih.gov/25964669/ PubMed]
 
===[[Myelodysplastic syndrome|Myelodysplastic syndrome (MDS)]]===
 
===[[Myelodysplastic syndrome|Myelodysplastic syndrome (MDS)]]===
−
*'''2019:''' Santini [https://doi.org/10.1182/blood-2018-03-785915 How I treat MDS after hypomethylating agent failure]
+
*'''2024:''' Mina et al. [https://doi.org/10.1182/blood.2023023005 How I reduce and treat posttransplant relapse of MDS] [https://pubmed.ncbi.nlm.nih.gov/38306658/ PubMed]
−
*'''2013:''' Sekeres & Cutler [http://www.bloodjournal.org/content/123/6/829.long How we treat higher-risk myelodysplastic syndromes] [https://pubmed.ncbi.nlm.nih.gov/24363399/ PubMed]
+
*'''2019:''' Santini. [https://doi.org/10.1182/blood-2018-03-785915 How I treat MDS after hypomethylating agent failure]
−
*'''2013:''' Fenaux & Adès [https://doi.org/10.1182/blood-2013-02-453068 How we treat lower-risk myelodysplastic syndromes]
+
*'''2018:''' Locatelli & Strahm. [https://doi.org/10.1182/blood-2017-09-765214 How I treat myelodysplastic syndromes of childhood] [https://pubmed.ncbi.nlm.nih.gov/29438960/ PubMed]
 +
*'''2018:''' Steensma. [https://doi.org/10.1182/blood-2018-06-860882 How I use molecular genetic tests to evaluate patients who have or may have myelodysplastic syndromes] [https://pubmed.ncbi.nlm.nih.gov/30185432/ PubMed]
 +
*'''2016:''' Peffault de Latour & Soulier. [https://doi.org/10.1182/blood-2016-01-583625 How I treat MDS and AML in Fanconi anemia] [https://pubmed.ncbi.nlm.nih.gov/27020090/ PubMed]
 +
*'''2013:''' Sekeres & Cutler. [http://www.bloodjournal.org/content/123/6/829.long How we treat higher-risk myelodysplastic syndromes] [https://pubmed.ncbi.nlm.nih.gov/24363399/ PubMed]
 +
*'''2013:''' Fenaux & Adès. [https://doi.org/10.1182/blood-2013-02-453068 How we treat lower-risk myelodysplastic syndromes]
 +
 
 +
===[[:Category:Myeloproliferative_neoplasms|Myeloproliferative neoplasms (MPNs)]]===
 +
*'''2024:''' Robinson et al. [https://doi.org/10.1182/blood.2023020729 How I treat myeloproliferative neoplasms in pregnancy] [https://pubmed.ncbi.nlm.nih.gov/38145575/ PubMed]
 +
*'''2018:''' Odenike. [https://doi.org/10.1182/blood-2018-03-785907 How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms] [https://pubmed.ncbi.nlm.nih.gov/30333119/ PubMed]
 +
 
 +
====[[Essential thrombocythemia|Essential thrombocythemia (ET)]]====
 +
*'''2016:''' Rumi & Cazzola. [https://doi.org/10.1182/blood-2016-05-643346 How I treat essential thrombocythemia] [https://pubmed.ncbi.nlm.nih.gov/27561316/ PubMed]
 +
 
 +
====[[Myelofibrosis|Myelofibrosis (MF)]]====
 +
*'''2023:''' Kröger et al. [https://doi.org/10.1182/blood.2023021218 How I treat transplant-eligible patients with myelofibrosis] [https://pubmed.ncbi.nlm.nih.gov/37647853/ PubMed]
 +
*'''2018:''' Pardanani & Tefferi. [https://doi.org/10.1182/blood-2018-02-785923 How I treat myelofibrosis after failure of JAK inhibitors] [https://pubmed.ncbi.nlm.nih.gov/29866811/ PubMed]
 +
*'''2011:''' Tefferi. [https://doi.org/10.1182/blood-2010-11-315614 How I treat myelofibrosis] [https://pubmed.ncbi.nlm.nih.gov/21200024/ PubMed]
  
−
===[[Polycythemia vera|Polycythemia vera (PV)]]===
+
====[[Polycythemia vera|Polycythemia vera (PV)]]====
−
*'''2014:''' Vannucchi [https://doi.org/10.1182/blood-2014-07-551929 How I treat polycythemia vera] [https://pubmed.ncbi.nlm.nih.gov/25278584/ PubMed]
+
*'''2019:''' Spivak. [https://doi.org/10.1182/blood.2018834044 How I treat polycythemia vera] [https://pubmed.ncbi.nlm.nih.gov/31151982/ PubMed]
 +
*'''2014:''' Vannucchi. [https://doi.org/10.1182/blood-2014-07-551929 How I treat polycythemia vera] [https://pubmed.ncbi.nlm.nih.gov/25278584/ PubMed]
 +
 
 +
===[[Systemic mastocytosis]]===
 +
*'''2013:''' Pardanani. [https://doi.org/10.1182/blood-2013-01-453183 How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage)] [https://pubmed.ncbi.nlm.nih.gov/23426950/ PubMed]
  
 
==Lymphoid neoplasms==
 
==Lymphoid neoplasms==
 
===[[Adult T-cell leukemia-lymphoma|Adult T-cell leukemia-lymphoma (ATLL)]]===
 
===[[Adult T-cell leukemia-lymphoma|Adult T-cell leukemia-lymphoma (ATLL)]]===
 
*'''2021:''' Cook & Phillips [https://doi.org/10.1182/blood.2019004045 How I treat adult T-cell leukemia/lymphoma] [https://pubmed.ncbi.nlm.nih.gov/33075812/ PubMed]
 
*'''2021:''' Cook & Phillips [https://doi.org/10.1182/blood.2019004045 How I treat adult T-cell leukemia/lymphoma] [https://pubmed.ncbi.nlm.nih.gov/33075812/ PubMed]
 +
 +
===[[Anaplastic large cell lymphoma]]===
 +
*'''2018:''' Metha-Shah et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6536699/ How I treat breast implant-associated anaplastic large cell lymphoma] [https://pubmed.ncbi.nlm.nih.gov/30209119/ PubMed]
 +
 +
===[[Burkitt lymphoma|Burkitt lymphoma (BL)]]===
 +
*'''2018:''' Gopal & Gross. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6053950/ How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa] [https://pubmed.ncbi.nlm.nih.gov/29769263/ PubMed]
 +
*'''2014:''' Jacobson & LaCasce. [https://doi.org/10.1182/blood-2014-06-538504 How I treat Burkitt lymphoma in adults] [https://pubmed.ncbi.nlm.nih.gov/25258344/ PubMed]
  
 
===[[Castleman disease]]===
 
===[[Castleman disease]]===
 +
*'''2022:''' Brandstadter & Fajgenbaum. [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc9584165/ How we manage idiopathic multicentric Castleman disease] [https://pubmed.ncbi.nlm.nih.gov/36125948/ PubMed]
 
*'''2010:''' Bower. [http://www.bloodjournal.org/content/116/22/4415.long  How I treat HIV-associated multicentric Castleman disease] [https://pubmed.ncbi.nlm.nih.gov/20688959/ PubMed]
 
*'''2010:''' Bower. [http://www.bloodjournal.org/content/116/22/4415.long  How I treat HIV-associated multicentric Castleman disease] [https://pubmed.ncbi.nlm.nih.gov/20688959/ PubMed]
  
Line 57: Line 106:
 
*'''2019:''' Stephens & Byrd. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6428663/ How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia]
 
*'''2019:''' Stephens & Byrd. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6428663/ How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia]
 
*'''2018:''' Brown. [https://doi.org/10.1182/blood-2017-08-764712 How I treat CLL patients with ibrutinib] [https://pubmed.ncbi.nlm.nih.gov/29255067/ PubMed]
 
*'''2018:''' Brown. [https://doi.org/10.1182/blood-2017-08-764712 How I treat CLL patients with ibrutinib] [https://pubmed.ncbi.nlm.nih.gov/29255067/ PubMed]
 +
*'''2018:''' Gribben. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6034643/ How and when I do allogeneic transplant in CLL] [https://pubmed.ncbi.nlm.nih.gov/29752258/ PubMed]
 +
*'''2017:''' Woyach. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5345730/ How I manage ibrutinib-refractory chronic lymphocytic leukemia] [https://pubmed.ncbi.nlm.nih.gov/28096090/ PubMed]
 +
*'''2009:''' Gribben. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc2941409/ How I treat CLL up front] [https://pubmed.ncbi.nlm.nih.gov/19850738/ PubMed]
 +
 +
===[[Classical Hodgkin lymphoma|Classical Hodgkin lymphoma (cHL)]]===
 +
*'''2021:''' Epperla & Herrera. [https://doi.org/10.1182/blood.2020007900 How I incorporate novel agents into the treatment of classical Hodgkin lymphoma]
 +
*'''2015:''' Alinari & Blum. [https://doi.org/10.1182/blood-2015-10-671826 How I treat relapsed classical Hodgkin lymphoma after autologous stem cell transplant] [https://pubmed.ncbi.nlm.nih.gov/26576863/ PubMed]
 +
*'''2014:''' Uldrick & Little. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4335078/ How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus] [https://pubmed.ncbi.nlm.nih.gov/25499453/ PubMed]
 +
 +
===[[CNS lymphoma]]===
 +
*'''2023:''' Alderuccio et al. [https://doi.org/10.1182/blood.2023020168 How I treat secondary CNS involvement by aggressive lymphomas] [https://pubmed.ncbi.nlm.nih.gov/37702537/ PubMed]
 +
*'''2017:''' Chin & Cheah. [https://doi.org/10.1182/blood-2017-03-737460 How I treat patients with aggressive lymphoma at high risk of CNS relapse] [https://pubmed.ncbi.nlm.nih.gov/28611025/ PubMed]
 +
*'''2013:''' Rubenstein et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3790503/ How I treat CNS lymphomas] [https://pubmed.ncbi.nlm.nih.gov/23963042/ PubMed]
  
 
===[[Cutaneous T-cell lymphoma|Cutaneous T-cell lymphoma (CTCL)]]===
 
===[[Cutaneous T-cell lymphoma|Cutaneous T-cell lymphoma (CTCL)]]===
−
*'''2019:''' Shinohara & Shustov [https://doi.org/10.1182/blood.2019000785 How I treat primary cutaneous CD30 + lymphoproliferative disorders]
+
*'''2019:''' Shinohara & Shustov. [https://doi.org/10.1182/blood.2019000785 How I treat primary cutaneous CD30 + lymphoproliferative disorders]
−
 
+
*'''2016:''' Whittaker et al. [https://doi.org/10.1182/blood-2015-12-611830 How I treat mycosis fungoides and Sézary syndrome] [https://pubmed.ncbi.nlm.nih.gov/27151889/ PubMed]
−
===Hodgkin lymphoma===
 
−
*'''2021:''' Epperla & Herrera [https://doi.org/10.1182/blood.2020007900 How I incorporate novel agents into the treatment of classical Hodgkin lymphoma]
 
−
*'''2020:''' Eichenauer & Engert [https://doi.org/10.1182/blood.2019004044 How I treat nodular lymphocyte-predominant Hodgkin Lymphoma]
 
  
 
===[[Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma (DLBCL)]]===
 
===[[Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma (DLBCL)]]===
−
*'''2023:''' Lugtenburg & Mutsaers [https://doi.org/10.1182/blood.2020008239 How I treat older patients with DLBCL in the frontline setting] [https://pubmed.ncbi.nlm.nih.gov/36413153/ PubMed]
+
*'''2023:''' Lugtenburg & Mutsaers. [https://doi.org/10.1182/blood.2020008239 How I treat older patients with DLBCL in the frontline setting] [https://pubmed.ncbi.nlm.nih.gov/36413153/ PubMed]
  
 
===[[Follicular lymphoma|Follicular lymphoma (FL)]]===
 
===[[Follicular lymphoma|Follicular lymphoma (FL)]]===
−
*'''2019:''' Casulo & Barr [https://doi.org/10.1182/blood-2018-08-822148 How I treat early-relapsing follicular lymphoma] [https://pubmed.ncbi.nlm.nih.gov/30700421/ PubMed]
+
*'''2019:''' Casulo & Barr. [https://doi.org/10.1182/blood-2018-08-822148 How I treat early-relapsing follicular lymphoma] [https://pubmed.ncbi.nlm.nih.gov/30700421/ PubMed]
 +
 
 +
===[[High-grade B-cell lymphoma|High-grade B-cell lymphoma (HGBL)]]===
 +
*'''2017:''' Friedberg. [https://doi.org/10.1182/blood-2017-04-737320 How I treat double-hit lymphoma] [https://pubmed.ncbi.nlm.nih.gov/28600333/ PubMed]
 +
 
 +
===[[HIV-associated lymphoma]]===
 +
*'''2014:''' Uldrick & Little. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4335078/ How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus] [https://pubmed.ncbi.nlm.nih.gov/25499453/ PubMed]
 +
*'''2012:''' Dunleavy & Wilson. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3321851/ How I treat HIV-associated lymphoma] [https://pubmed.ncbi.nlm.nih.gov/22337719/ PubMed]
 +
*'''2010:''' Bower. [http://www.bloodjournal.org/content/116/22/4415.long  How I treat HIV-associated multicentric Castleman disease] [https://pubmed.ncbi.nlm.nih.gov/20688959/ PubMed]
  
 
===[[Large granular lymphocytic leukemia|Large granular lymphocytic leukemia (T-LGL)]]===
 
===[[Large granular lymphocytic leukemia|Large granular lymphocytic leukemia (T-LGL)]]===
 
*'''2011:''' Lamy & Loughran. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062292/ How I treat LGL leukemia] [https://pubmed.ncbi.nlm.nih.gov/21190991/ PubMed]
 
*'''2011:''' Lamy & Loughran. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062292/ How I treat LGL leukemia] [https://pubmed.ncbi.nlm.nih.gov/21190991/ PubMed]
  
−
===[[NK- and T-cell lymphoma]]===
+
===[[Mantle cell lymphoma|Mantle cell lymphoma (MCL)]]===
−
*'''2013:''' Tse & Kwong [http://www.bloodjournal.org/content/121/25/4997.long How I treat NK/T-cell lymphomas] [https://pubmed.ncbi.nlm.nih.gov/23652805/ PubMed]
+
*'''2009:''' Ghielmini & Zucca. [https://doi.org/10.1182/blood-2009-02-179739 How I treat mantle cell lymphoma] [https://pubmed.ncbi.nlm.nih.gov/19556426/ PubMed]
 +
 
 +
===[[NK- and T-cell lymphoma|NK- and T-cell lymphoma (NKTCL)]]===
 +
*'''2013:''' Tse & Kwong. [http://www.bloodjournal.org/content/121/25/4997.long How I treat NK/T-cell lymphomas] [https://pubmed.ncbi.nlm.nih.gov/23652805/ PubMed]
 +
 
 +
===[[Hodgkin lymphoma, nodular lymphocyte-predominant|Nodular lymphocyte-predominant Hodgkin lymphoma (NLP-HL)]]===
 +
*'''2020:''' Eichenauer & Engert. [https://doi.org/10.1182/blood.2019004044 How I treat nodular lymphocyte-predominant Hodgkin Lymphoma]
 +
*'''2013:''' Advani & Hoppe. [https://doi.org/10.1182/blood-2013-07-453241 How I treat nodular lymphocyte predominant Hodgkin lymphoma] [https://pubmed.ncbi.nlm.nih.gov/24215035/ PubMed]
 +
 
 +
===[[Peripheral T-cell lymphoma|Peripheral T-cell lymphoma (PTCL)]]===
 +
*'''2014:''' Moskowitz et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4507040/ How I treat the peripheral T-cell lymphomas] [https://pubmed.ncbi.nlm.nih.gov/24615779/ PubMed]
 +
 
 +
===[[Post-transplant lymphoproliferative disorder|Post-transplant lymphoproliferative disorder (PTLD)]]===
 +
*'''2023:''' Amengual & Pro. [https://doi.org/10.1182/blood.2023020075 How I treat posttransplant lymphoproliferative disorder] [https://pubmed.ncbi.nlm.nih.gov/37540819/ PubMed]
 +
*'''2015:''' Dierickx et al. [https://doi.org/10.1182/blood-2015-05-615872 How I treat posttransplant lymphoproliferative disorders] [https://pubmed.ncbi.nlm.nih.gov/26384356/ PubMed]
 +
 
 +
===[[Primary mediastinal B-cell lymphoma|Primary mediastinal B-cell lymphoma (PMBCL)]]===
 +
*'''2018:''' Giulino-Roth. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6634954/ How I treat primary mediastinal B-cell lymphoma] [https://pubmed.ncbi.nlm.nih.gov/29976557/ PubMed]
  
 
===[[T-cell prolymphocytic leukemia|Prolymphocytic leukemia (T-PLL)]]===
 
===[[T-cell prolymphocytic leukemia|Prolymphocytic leukemia (T-PLL)]]===
−
*'''2012:''' Dearden [https://doi.org/10.1182/blood-2012-01-380139 How I treat prolymphocytic leukemia] [https://pubmed.ncbi.nlm.nih.gov/22649104/ PubMed]
+
*'''2012:''' Dearden. [https://doi.org/10.1182/blood-2012-01-380139 How I treat prolymphocytic leukemia] [https://pubmed.ncbi.nlm.nih.gov/22649104/ PubMed]
 +
 
 +
===Splenic lymphoma===
 +
*'''2011:''' Iannitto & Tripodo. [https://doi.org/10.1182/blood-2010-09-271437 How I diagnose and treat splenic lymphomas] [https://pubmed.ncbi.nlm.nih.gov/21119113/ PubMed]
 +
 
 +
===[[Transformed lymphoma]]===
 +
*'''2014:''' Parikh et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3954047/ How we treat Richter syndrome] [https://pubmed.ncbi.nlm.nih.gov/24421328/ PubMed]
  
 
===[[Waldenström macroglobulinemia|Waldenström macroglobulinemia (WM)]]===
 
===[[Waldenström macroglobulinemia|Waldenström macroglobulinemia (WM)]]===
 +
*'''2024:''' Treon et al. [https://doi.org/10.1182/blood.2022017235 How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia] [https://pubmed.ncbi.nlm.nih.gov/38211337/ PubMed]
 
*'''2019:''' Dimopoulos & Kastritis. [https://doi.org/10.1182/blood.2019000725 How I treat Waldenström macroglobulinemia] [https://pubmed.ncbi.nlm.nih.gov/31527073/ PubMed]
 
*'''2019:''' Dimopoulos & Kastritis. [https://doi.org/10.1182/blood.2019000725 How I treat Waldenström macroglobulinemia] [https://pubmed.ncbi.nlm.nih.gov/31527073/ PubMed]
 +
*'''2015:''' Treon. [https://doi.org/10.1182/blood-2015-01-553974 How I treat Waldenström macroglobulinemia] [https://pubmed.ncbi.nlm.nih.gov/26002963/ PubMed]
  
 
==Plasma cell dyscrasias==
 
==Plasma cell dyscrasias==
 
===[[Light-chain (AL) amyloidosis]]===
 
===[[Light-chain (AL) amyloidosis]]===
−
*'''2022:''' Palladini & Merlini [https://doi.org/10.1182/blood.2020008737 How I treat AL amyloidosis]
+
*'''2022:''' Palladini & Merlini. [https://doi.org/10.1182/blood.2020008737 How I treat AL amyloidosis]
 +
*'''2012:''' Leung et al. [https://doi.org/10.1182/blood-2012-03-413682 How I treat amyloidosis: the importance of accurate diagnosis and amyloid typing] [https://pubmed.ncbi.nlm.nih.gov/22948045/ PubMed]
  
−
===[[Multiple myeloma]]===
+
===MGUS===
−
*'''2023:''' van de Donk [https://doi.org/10.1200/jco.22.02114 How We Manage Newly Diagnosed Multiple Myeloma With Circulating Tumor Cells]
+
*'''2013:''' Fermand et al. [https://doi.org/10.1182/blood-2013-05-495929 How I treat monoclonal gammopathy of renal significance (MGRS)] [https://pubmed.ncbi.nlm.nih.gov/24108460/ PubMed]
 +
 
 +
===[[Multiple myeloma|Multiple myeloma (MM)]]===
 +
*'''2024:''' Facon et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10808246/ How I treat multiple myeloma in geriatric patients] [https://pubmed.ncbi.nlm.nih.gov/36693134/ PubMed]
 +
**'''2010:''' Mehta et al. [https://doi.org/10.1182/blood-2009-10-163329 How I treat elderly patients with myeloma] [https://pubmed.ncbi.nlm.nih.gov/20644120/ PubMed]
 +
*'''2023:''' van de Donk. [https://doi.org/10.1200/jco.22.02114 How We Manage Newly Diagnosed Multiple Myeloma With Circulating Tumor Cells]
 +
*'''2022:''' Kastritis et al. [https://doi.org/10.1182/blood.2020008734 How I treat relapsed multiple myeloma]
 +
**'''2014:''' Bladé et al. [https://doi.org/10.1182/blood-2014-10-551531 How I treat relapsed myeloma] [https://pubmed.ncbi.nlm.nih.gov/25587037/ PubMed]
 +
*'''2022:''' Perrot. [https://doi.org/10.1182/blood.2020008735 How I treat frontline transplantation-eligible multiple myeloma] [https://pubmed.ncbi.nlm.nih.gov/34788422/ PubMed]
 +
*'''2022:''' Vaxman & Gertz. [https://doi.org/10.1182/blood.2021011670 How I approach smoldering multiple myeloma]
 
*'''2022:''' Zamagni et al. [https://doi.org/10.1182/blood.2020008733 How I treat high-risk multiple myeloma]
 
*'''2022:''' Zamagni et al. [https://doi.org/10.1182/blood.2020008733 How I treat high-risk multiple myeloma]
−
*'''2022:''' Kastritis et al. [https://doi.org/10.1182/blood.2020008734 How I treat relapsed multiple myeloma]
+
**'''2015:''' Lonial et al. [https://doi.org/10.1182/blood-2015-06-653261 How I treat high-risk myeloma] [https://pubmed.ncbi.nlm.nih.gov/26272217/ PubMed]
−
*'''2022:''' Vaxman & Gertz [https://doi.org/10.1182/blood.2021011670 How I approach smoldering multiple myeloma]
+
*'''2017:''' Harousseau & Attal. [https://doi.org/10.1182/blood-2017-03-726703 How I treat first relapse of myeloma] [https://pubmed.ncbi.nlm.nih.gov/28679737/ PubMed]
 +
*'''2017:''' Moreau. [https://doi.org/10.1182/blood-2017-05-743203 How I treat myeloma with new agents] [https://pubmed.ncbi.nlm.nih.gov/28747306/ PubMed]
 +
*'''2015:''' Larocca & Palumbo. [https://doi.org/10.1182/blood-2015-05-612960 How I treat fragile myeloma patients] [https://pubmed.ncbi.nlm.nih.gov/26324701/ PubMed]
 +
*'''2015:''' Touzeau & Moreau. [https://doi.org/10.1182/blood-2015-07-635383 How I treat extramedullary myeloma] [https://pubmed.ncbi.nlm.nih.gov/26679866/ PubMed]
 +
*'''2014:''' Gertz & Dingli. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4126328/ How we manage autologous stem cell transplantation for patients with multiple myeloma] [https://pubmed.ncbi.nlm.nih.gov/24973360/ PubMed]
 +
*'''2009:''' Stewart et al. [https://doi.org/10.1182/blood-2009-07-204651 How I treat multiple myeloma in younger patients] [https://pubmed.ncbi.nlm.nih.gov/19861683/ PubMed]
 +
 
 +
===[[Plasma cell leukemia|Plasma cell leukemia (PCL)]]===
 +
*'''2012:''' van de Donk et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3757364/ How I treat plasma cell leukemia] [https://pubmed.ncbi.nlm.nih.gov/22837533/ PubMed]
 +
 
 +
===[[Smoldering multiple myeloma|Smoldering multiple myeloma (SMM)]]===
 +
*'''2014:''' Ghobrial & Landgren. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4246036/ How I treat smoldering multiple myeloma] [https://pubmed.ncbi.nlm.nih.gov/25298034/ PubMed]
  
 
==Histiocytic disorders==
 
==Histiocytic disorders==
 
===[[Hemophagocytic lymphohistiocytosis|Hemophagocytic lymphohistiocytosis (HLH)]]===
 
===[[Hemophagocytic lymphohistiocytosis|Hemophagocytic lymphohistiocytosis (HLH)]]===
 
*'''2015:''' Schram & Berliner. [https://doi.org/10.1182/blood-2015-01-551622 How I treat hemophagocytic lymphohistiocytosis in the adult patient] [https://pubmed.ncbi.nlm.nih.gov/25758828/ PubMed]
 
*'''2015:''' Schram & Berliner. [https://doi.org/10.1182/blood-2015-01-551622 How I treat hemophagocytic lymphohistiocytosis in the adult patient] [https://pubmed.ncbi.nlm.nih.gov/25758828/ PubMed]
 +
 +
===[[Langerhans cell histiocytosis|Langerhans cell histiocytosis (LCH)]]===
 +
*'''2015:''' Allen et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4492195/ How I treat Langerhans cell histiocytosis] [https://pubmed.ncbi.nlm.nih.gov/25827831/ PubMed]
  
 
=Classical hematology=
 
=Classical hematology=
 
==Hemostasis and thrombosis==
 
==Hemostasis and thrombosis==
 +
*'''2023:''' Samuelson Bannow & Konkle. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10562531/ How I approach bleeding in hospitalized patients] [https://pubmed.ncbi.nlm.nih.gov/36652635/ PubMed]
 +
*'''2021:''' Baker & O'Donnell. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9642789/ How I treat bleeding disorder of unknown cause] [https://pubmed.ncbi.nlm.nih.gov/34398949/ PubMed]
 +
*'''2016:''' Martin & Key. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4946199/ How I treat patients with inherited bleeding disorders who need anticoagulant therapy] [https://pubmed.ncbi.nlm.nih.gov/27106121/ PubMed]
 +
*'''2015:''' Pavord & Maybury. [https://doi.org/10.1182/blood-2014-10-512608 How I treat postpartum hemorrhage] [https://pubmed.ncbi.nlm.nih.gov/25769619/ PubMed]
 +
*'''2014:''' Johansson et al. [https://doi.org/10.1182/blood-2014-05-575340 How I treat patients with massive hemorrhage] [https://pubmed.ncbi.nlm.nih.gov/25293771/ PubMed]
 +
*'''2014:''' Levy & Goodnough. [https://doi.org/10.1182/blood-2014-08-552000 How I use fibrinogen replacement therapy in acquired bleeding] [https://pubmed.ncbi.nlm.nih.gov/25519751/ PubMed]
 
===[[Acquired thrombotic thrombocytopenic purpura|Acquired thrombotic thrombocytopenic purpura (aTTP)]]===
 
===[[Acquired thrombotic thrombocytopenic purpura|Acquired thrombotic thrombocytopenic purpura (aTTP)]]===
 
*'''2022:''' Akwaa et al. [https://doi.org/10.1182/blood.2021014514 How I treat immune-mediated thrombotic thrombocytopenic purpura after hospital discharge]
 
*'''2022:''' Akwaa et al. [https://doi.org/10.1182/blood.2021014514 How I treat immune-mediated thrombotic thrombocytopenic purpura after hospital discharge]
 
*'''2020:''' Ferrari & Peyvandi. [https://doi.org/10.1182/blood.2019000962 How I treat thrombotic thrombocytopenic purpura in pregnancy]
 
*'''2020:''' Ferrari & Peyvandi. [https://doi.org/10.1182/blood.2019000962 How I treat thrombotic thrombocytopenic purpura in pregnancy]
 +
*'''2015:''' Sayani & Abrams. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4473115/ How I treat refractory thrombotic thrombocytopenic purpura] [https://pubmed.ncbi.nlm.nih.gov/25784681/ PubMed]
 +
 
===[[Antiphospholipid antibody syndrome|Antiphospholipid antibody syndrome (APS)]]===
 
===[[Antiphospholipid antibody syndrome|Antiphospholipid antibody syndrome (APS)]]===
 +
*'''2024:''' Branch & Lim [https://doi.org/10.1182/blood.2023020727 How I diagnose and treat antiphospholipid syndrome in pregnancy] [https://pubmed.ncbi.nlm.nih.gov/38145574/ PubMed]
 
*'''2021:''' Cohen & Isenberg. [https://doi.org/10.1182/blood.2020004942 How I treat anticoagulant-refractory thrombotic antiphospholipid syndrome] [https://pubmed.ncbi.nlm.nih.gov/32898856/ PubMed]
 
*'''2021:''' Cohen & Isenberg. [https://doi.org/10.1182/blood.2020004942 How I treat anticoagulant-refractory thrombotic antiphospholipid syndrome] [https://pubmed.ncbi.nlm.nih.gov/32898856/ PubMed]
 +
*'''2015:''' Ortel et al. [https://doi.org/10.1182/blood-2014-09-551978 How I treat catastrophic thrombotic syndromes] [https://pubmed.ncbi.nlm.nih.gov/26179082/ PubMed]
 +
 +
===Arterial thromboembolism (ATE)===
 +
*'''2020:''' May & Moll. [https://doi.org/10.1182/blood.2019000820 How I treat unexplained arterial thrombosis]
 +
===Disseminated intravascular coagulation (DIC)===
 +
*'''2018:''' Levi & Scully. [https://doi.org/10.1182/blood-2017-10-804096 How I treat disseminated intravascular coagulation] [https://pubmed.ncbi.nlm.nih.gov/29255070/ PubMed]
 
===[[Inherited coagulopathy|Hemophilia]]===
 
===[[Inherited coagulopathy|Hemophilia]]===
 
*'''2020:''' Leebeek et al. [https://doi.org/10.1182/blood.2019000964 How I manage pregnancy in carriers of hemophilia and patients with von Willebrand disease]
 
*'''2020:''' Leebeek et al. [https://doi.org/10.1182/blood.2019000964 How I manage pregnancy in carriers of hemophilia and patients with von Willebrand disease]
 
*'''2019:''' Young. [https://doi.org/10.1111/bjh.15942 How I treat children with haemophilia and inhibitors]
 
*'''2019:''' Young. [https://doi.org/10.1111/bjh.15942 How I treat children with haemophilia and inhibitors]
 +
*'''2015:''' Leissinger et al. [https://doi.org/10.1182/blood-2014-10-551952 How I use bypassing therapy for prophylaxis in patients with hemophilia A and inhibitors] [https://pubmed.ncbi.nlm.nih.gov/25827834/ PubMed]
 +
*'''2012:''' Mannucci & Mancuso. [https://doi.org/10.1182/blood-2012-01-394411 How we choose factor VIII to treat hemophilia] [https://pubmed.ncbi.nlm.nih.gov/22411872/ PubMed]
 +
 +
===[[Heparin-induced thrombocytopenia|Heparin-induced thrombocytopenia (HIT)]]===
 +
*'''2016:''' Warkentin & Anderson. [https://doi.org/10.1182/blood-2016-01-635003 How I treat patients with a history of heparin-induced thrombocytopenia] [https://pubmed.ncbi.nlm.nih.gov/27114458/ PubMed]
 +
 
===[[Thrombotic microangiopathy|Thrombotic microangiopathy (TMA)]]===
 
===[[Thrombotic microangiopathy|Thrombotic microangiopathy (TMA)]]===
 
*'''2023:''' Doreille et al. [https://doi.org/10.1182/blood.2022015583 How I treat thrombotic microangiopathy in the era of rapid genomics]
 
*'''2023:''' Doreille et al. [https://doi.org/10.1182/blood.2022015583 How I treat thrombotic microangiopathy in the era of rapid genomics]
−
*'''2021:''' Thomas & Scully. [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8555418/ How I treat microangiopathic hemolytic anemia in patients with cancer]
+
*'''2021:''' Thomas & Scully. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8555418/ How I treat microangiopathic hemolytic anemia in patients with cancer]
 
===[[Venous thromboembolism|Venous thromboembolism (VTE)]]===
 
===[[Venous thromboembolism|Venous thromboembolism (VTE)]]===
 +
*'''2024:''' Bhat et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10862368/ How I treat pediatric venous thromboembolism in the DOAC era] [https://pubmed.ncbi.nlm.nih.gov/37390311/ PubMed]
 +
**'''2017:''' Young. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5813720/ How I treat pediatric venous thromboembolism] [https://pubmed.ncbi.nlm.nih.gov/28774877/ PubMed]
 +
*'''2023:''' Akpan & Hunt. [https://doi.org/10.1182/blood.2021014835 How I approach the prevention and treatment of thrombotic complications in hospitalized patients] [https://pubmed.ncbi.nlm.nih.gov/37339577/ PubMed]
 
*'''2022:''' Schmidt & Lee. [https://doi.org/10.1182/blood.2019003689 How I treat and prevent venous thrombotic complications in patients with lymphoma]
 
*'''2022:''' Schmidt & Lee. [https://doi.org/10.1182/blood.2019003689 How I treat and prevent venous thrombotic complications in patients with lymphoma]
 
*'''2020:''' Klok & Huisman. [https://doi.org/10.1182/blood.2019001605 How I assess and manage the risk of bleeding in patients treated for venous thromboembolism]
 
*'''2020:''' Klok & Huisman. [https://doi.org/10.1182/blood.2019001605 How I assess and manage the risk of bleeding in patients treated for venous thromboembolism]
Line 118: Line 258:
 
*'''2019:''' Chan & Eikelbloom. [https://doi.org/10.1182/blood-2019-01-846048 How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism]
 
*'''2019:''' Chan & Eikelbloom. [https://doi.org/10.1182/blood-2019-01-846048 How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism]
 
*'''2019:''' Kraaijpoel & Carrier. [https://doi.org/10.1182/blood-2018-08-835595 How I treat cancer-associated venous thromboembolism]
 
*'''2019:''' Kraaijpoel & Carrier. [https://doi.org/10.1182/blood-2018-08-835595 How I treat cancer-associated venous thromboembolism]
−
*'''2018:''' Shet & Wun. [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6202908/ How I diagnose and treat venous thromboembolism in sickle cell disease]
+
*'''2018:''' Rabinovich & Kahn. [https://doi.org/10.1182/blood-2018-01-785956 How I treat the postthrombotic syndrome] [https://pubmed.ncbi.nlm.nih.gov/29545327/ PubMed]
 +
*'''2018:''' Shet & Wun. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6202908/ How I diagnose and treat venous thromboembolism in sickle cell disease]
 +
*'''2018:''' Vedantham & Sista. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5814931/ How I use catheter-directed interventional therapy to treat patients with venous thromboembolism] [https://pubmed.ncbi.nlm.nih.gov/29295847/ PubMed]
 +
*'''2017:''' Schulman. [https://doi.org/10.1182/blood-2017-03-742304 How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy] [https://pubmed.ncbi.nlm.nih.gov/28483766/ PubMed]
 +
*'''2015:''' Kyrle. [https://doi.org/10.1182/blood-2015-09-671297 How I treat recurrent deep-vein thrombosis] [https://pubmed.ncbi.nlm.nih.gov/26660685/ PubMed]
 +
*'''2015:''' O'Connell. [https://doi.org/10.1182/blood-2014-08-551879 How I treat incidental pulmonary embolism] [https://pubmed.ncbi.nlm.nih.gov/25533036/ PubMed]
 +
*'''2014:''' Ageno et al. [https://doi.org/10.1182/blood-2014-07-551515 How I treat splanchnic vein thrombosis] [https://pubmed.ncbi.nlm.nih.gov/25320239/ PubMed]
 +
*'''2014:''' Palareti. [https://doi.org/10.1182/blood-2013-10-512616 How I treat isolated distal deep vein thrombosis (IDDVT)] [https://pubmed.ncbi.nlm.nih.gov/24472834/ PubMed]
 +
*'''2012:''' Dobromirski & Cohen. [https://doi.org/10.1182/blood-2012-03-378901 How I manage venous thromboembolism risk in hospitalized medical patients] [https://pubmed.ncbi.nlm.nih.gov/22705598/ PubMed]
 +
 
 
===[[Inherited coagulopathy|von Willebrand disease (vWD)]]===
 
===[[Inherited coagulopathy|von Willebrand disease (vWD)]]===
 +
*'''2024:''' Poston & Kruse-Jarres [https://doi.org/10.1182/blood.2022018534 How I treat von Willebrand disorders in older adults] [https://pubmed.ncbi.nlm.nih.gov/37672774/ PubMed]
 +
*'''2020:''' Biguzzi et al. [https://doi.org/10.1182/blood.2019003702 How I treat gastrointestinal bleeding in congenital and acquired von Willebrand disease]
 
*'''2020:''' Leebeek et al. [https://doi.org/10.1182/blood.2019000964 How I manage pregnancy in carriers of hemophilia and patients with von Willebrand disease]
 
*'''2020:''' Leebeek et al. [https://doi.org/10.1182/blood.2019000964 How I manage pregnancy in carriers of hemophilia and patients with von Willebrand disease]
 
*'''2019:''' Lavin & O'Donnell. [https://doi.org/10.1182/blood-2018-10-844936 How I treat low von Willebrand factor levels]
 
*'''2019:''' Lavin & O'Donnell. [https://doi.org/10.1182/blood-2018-10-844936 How I treat low von Willebrand factor levels]
 +
*'''2018:''' Kruse-Jarres & Johnsen. [https://doi.org/10.1182/blood-2017-06-742692 How I treat type 2B von Willebrand disease] [https://pubmed.ncbi.nlm.nih.gov/29378695/ PubMed]
 +
*'''2014:''' Tosetto & Castaman. [https://doi.org/10.1182/blood-2014-08-551960 How I treat type 2 variant forms of von Willebrand disease] [https://pubmed.ncbi.nlm.nih.gov/25477497/ PubMed]
 +
*'''2011:''' Tiede et al. [https://doi.org/10.1182/blood-2010-11-297580 How I treat the acquired von Willebrand syndrome] [https://pubmed.ncbi.nlm.nih.gov/21540459/ PubMed]
  
 
==Cytopenias==
 
==Cytopenias==
 +
===Acquired pure red cell aplasia===
 +
*'''2021:''' Gurnari & Maciejewski. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8057257/ How I manage acquired pure red cell aplasia in adults] [https://pubmed.ncbi.nlm.nih.gov/33657207/ PubMed]
 +
 +
===[[Anemia]]===
 +
*'''2024:''' Oyedeji et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10808247/ How I treat anemia in older adults] [https://pubmed.ncbi.nlm.nih.gov/36827619/ PubMed]
 +
*'''2023:''' Carson & Brittenham. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10485845/ How I treat anemia with red blood cell transfusion and iron] [https://pubmed.ncbi.nlm.nih.gov/36315909/ PubMed]
 +
*'''2021:''' Gurnari & Maciejewski. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8057257/ How I manage acquired pure red cell aplasia in adults]
 +
*'''2020:''' Anand & Gupta. [https://doi.org/10.1182/blood.2019004004 How I treat anemia in heart failure]
 +
*'''2020:''' Fishbane & Coyne. [https://doi.org/10.1182/blood.2019004330 How I treat renal anemia]
 +
*'''2020:''' Gilreath & Rodgers. [https://doi.org/10.1182/blood.2019004017 How I treat cancer-associated anemia]
 +
*'''2020:''' Shander et al. [https://doi.org/10.1182/blood.2019003945 How I treat anemia in the perisurgical setting]
 +
*'''2016:''' Achebe & Gafter-Gvili. [https://doi.org/10.1182/blood-2016-08-672246 How I treat anemia in pregnancy: iron, cobalamin, and folate] [https://pubmed.ncbi.nlm.nih.gov/28034892/ PubMed]
 +
*'''2014:''' Hershko & Camaschella. [https://doi.org/10.1182/blood-2013-10-512624 How I treat unexplained refractory iron deficiency anemia]
  
 +
===[[Aplastic anemia]]===
 +
*'''2017:''' Bacigalupo. [https://doi.org/10.1182/blood-2016-08-693481 How I treat acquired aplastic anemia] [https://pubmed.ncbi.nlm.nih.gov/28096088/ PubMed]
 
===[[Autoimmune cytopenia]]===
 
===[[Autoimmune cytopenia]]===
 
*'''2022:''' Porpaczy & Jäger. [https://doi.org/10.1182/blood.2019003686 How I manage autoimmune cytopenias in patients with lymphoid cancer] [https://pubmed.ncbi.nlm.nih.gov/34517415/ PubMed]
 
*'''2022:''' Porpaczy & Jäger. [https://doi.org/10.1182/blood.2019003686 How I manage autoimmune cytopenias in patients with lymphoid cancer] [https://pubmed.ncbi.nlm.nih.gov/34517415/ PubMed]
Line 130: Line 299:
 
===[[Immune thrombocytopenia|Immune thrombocytopenia (ITP)]]===
 
===[[Immune thrombocytopenia|Immune thrombocytopenia (ITP)]]===
 
*'''2021:''' Ghanima et al. [https://doi.org/10.1182/blood.2021010968 How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment]
 
*'''2021:''' Ghanima et al. [https://doi.org/10.1182/blood.2021010968 How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment]
 +
*'''2016:''' Cuker & Neunert. [https://doi.org/10.1182/blood-2016-03-603365 How I treat refractory immune thrombocytopenia] [https://pubmed.ncbi.nlm.nih.gov/27053529/ PubMed]
 +
 +
===[[Neutropenia & leukopenia]]===
 +
*'''2014:''' Gibson & Berliner. [https://doi.org/10.1182/blood-2014-02-482612 How we evaluate and treat neutropenia in adults] [https://pubmed.ncbi.nlm.nih.gov/24869938/ PubMed]
 +
 +
===[[Thrombocytopenia and platelet dysfunction]]===
 +
*'''2024:''' Foy et al. [https://doi.org/10.1182/blood.2022017634 How I diagnose and treat thrombocytopenia in geriatric patients] [https://pubmed.ncbi.nlm.nih.gov/37956435/ PubMed]
 +
*'''2024:''' Fogerty & Kuter [https://doi.org/10.1182/blood.2023020726 How I treat thrombocytopenia in pregnancy] [https://pubmed.ncbi.nlm.nih.gov/37992219/ PubMed]
 +
**'''2012:''' Gernsheimer et al. [https://doi.org/10.1182/blood-2012-08-448944 How I treat thrombocytopenia in pregnancy] [https://pubmed.ncbi.nlm.nih.gov/23149846/ PubMed]
 +
*'''2023:''' Stanworth & Mumford. [https://doi.org/10.1182/blood.2022018017 How I diagnose and treat neonatal thrombocytopenia] [https://pubmed.ncbi.nlm.nih.gov/36787503/ PubMed]
 +
*'''2022:''' Stanworth & Shah. [https://doi.org/10.1182/blood.2022016558 How I use platelet transfusions] [https://pubmed.ncbi.nlm.nih.gov/35926105/ PubMed]
 +
*'''2022:''' Fiore et al. [https://doi.org/10.1182/blood.2021011595 How I manage pregnancy in women with Glanzmann thrombasthenia]
 +
*'''2021:''' Kyrle & Eichinger. [https://doi.org/10.1182/blood.2020008218 How I manage cyclic thrombocytopenia]
 +
*'''2016:''' Greinacher & Selleng. [https://doi.org/10.1182/blood-2016-09-693655 How I evaluate and treat thrombocytopenia in the intensive care unit patient] [https://pubmed.ncbi.nlm.nih.gov/28034871/ PubMed]
 +
 +
===[[WHIM syndrome]]===
 +
*'''2017:''' Badolato et al. [https://doi.org/10.1182/blood-2017-02-708552 How I treat warts, hypogammaglobulinemia, infections, and myelokathexis syndrome] [https://pubmed.ncbi.nlm.nih.gov/29066537/ PubMed]
 +
 +
==Hemoglobinopathies==
 +
 +
===[[Beta thalassemia]]===
 +
*'''2023:''' Saliba et al. [https://doi.org/10.1182/blood.2023020683 How I treat non-transfusion-dependent β-thalassemia] [https://pubmed.ncbi.nlm.nih.gov/37478396/ PubMed]
 +
*'''2018:''' Taher & Cappellini. [https://doi.org/10.1182/blood-2018-06-818187 How I manage medical complications of β-thalassemia in adults] [https://pubmed.ncbi.nlm.nih.gov/30206117/ PubMed]
 +
 +
===[[Sickle cell anemia|Sickle cell disease]]===
 +
*'''2024:''' James & Strouse [https://doi.org/10.1182/blood.2023020728 How I treat sickle cell disease in pregnancy] [https://pubmed.ncbi.nlm.nih.gov/37979134/ PubMed]
 +
*'''2019:''' Stenger et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6923666/ How I treat sickle cell disease with hematopoietic cell transplantation]
 +
*'''2018:''' Pirenne & Yazdanbakhsh. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6014354/ How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions] [https://pubmed.ncbi.nlm.nih.gov/29724898/ PubMed]
 +
*'''2018:''' Shet & Wun. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6202908/ How I diagnose and treat venous thromboembolism in sickle cell disease]
 +
*'''2018:''' Thein & Howard. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6202910/ How I treat the older adult with sickle cell disease]
 +
*'''2015:''' Anele et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4458797/ How I treat priapism] [https://pubmed.ncbi.nlm.nih.gov/25810489/ PubMed]
 +
*'''2015:''' Kassim et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4467906/ How I treat and manage strokes in sickle cell disease] [https://pubmed.ncbi.nlm.nih.gov/25824688/ PubMed]
 +
*'''2014:''' Sharpe & Thein. [https://doi.org/10.1182/blood-2014-02-557439 How I treat renal complications in sickle cell disease] [https://pubmed.ncbi.nlm.nih.gov/24764565/ PubMed]
  
 
==Hemolytic disorders==
 
==Hemolytic disorders==
−
 
+
*'''2018:''' Machogu & Machado. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6202915/ How I treat hypoxia in adults with hemoglobinopathies and hemolytic disorders] [https://pubmed.ncbi.nlm.nih.gov/30206115/ PubMed]
 +
*'''2017:''' Go et al. [https://doi.org/10.1182/blood-2016-11-693689 How I treat autoimmune hemolytic anemia] [https://pubmed.ncbi.nlm.nih.gov/28360039/ PubMed]
 
===[[Cold agglutinin disease|Cold agglutinin disease (CAD)]]===
 
===[[Cold agglutinin disease|Cold agglutinin disease (CAD)]]===
−
*'''2021:''' Berentsen [https://doi.org/10.1182/blood.2019003809 How I treat cold agglutinin disease]
+
*'''2021:''' Berentsen. [https://doi.org/10.1182/blood.2019003809 How I treat cold agglutinin disease]
  
 
===[[Atypical hemolytic uremic syndrome|Atypical hemolytic uremic syndrome (aHUS)]]===
 
===[[Atypical hemolytic uremic syndrome|Atypical hemolytic uremic syndrome (aHUS)]]===
 
*'''2023:''' Fakhouri et al. [https://doi.org/10.1182/blood.2022017860 How I diagnose and treat atypical hemolytic uremic syndrome] [https://pubmed.ncbi.nlm.nih.gov/36322940/ PubMed]
 
*'''2023:''' Fakhouri et al. [https://doi.org/10.1182/blood.2022017860 How I diagnose and treat atypical hemolytic uremic syndrome] [https://pubmed.ncbi.nlm.nih.gov/36322940/ PubMed]
 +
*'''2014:''' Cataland & Wu. [https://doi.org/10.1182/blood-2013-11-516237 How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome] [https://pubmed.ncbi.nlm.nih.gov/24599547/ PubMed]
  
 
===[[Paroxysmal nocturnal hemoglobinuria|Paroxysmal nocturnal hemoglobinuria (PNH)]]===
 
===[[Paroxysmal nocturnal hemoglobinuria|Paroxysmal nocturnal hemoglobinuria (PNH)]]===
−
*'''2021:''' Brodsky [https://doi.org/10.1182/blood.2019003812 How I treat paroxysmal nocturnal hemoglobinuria]
+
*'''2021:''' Brodsky. [https://doi.org/10.1182/blood.2019003812 How I treat paroxysmal nocturnal hemoglobinuria]
 +
*'''2009:''' Brodsky. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc2710914/ How I treat paroxysmal nocturnal hemoglobinuria] [https://pubmed.ncbi.nlm.nih.gov/19372253/ PubMed]
  
 
===[[Warm autoimmune hemolytic anemia|Warm autoimmune hemolytic anemia (WAIHA)]]===
 
===[[Warm autoimmune hemolytic anemia|Warm autoimmune hemolytic anemia (WAIHA)]]===
−
*'''2021:''' Barcellini & Fattizzo [https://doi.org/10.1182/blood.2019003808 How I treat warm autoimmune hemolytic anemia]
+
*'''2021:''' Barcellini & Fattizzo. [https://doi.org/10.1182/blood.2019003808 How I treat warm autoimmune hemolytic anemia]
  
 
=Special considerations=
 
=Special considerations=
−
==Complications of treatment==
 
  
−
==Pediatrics==
+
==Age-based recommendations==
 +
''The majority of How I Treat articles focus on "standard" adults; below, articles that focus on other age populations are concatenated.''
 +
===Neonates===
 +
*'''2023:''' Stanworth & Mumford [https://doi.org/10.1182/blood.2022018017 How I diagnose and treat neonatal thrombocytopenia] [https://pubmed.ncbi.nlm.nih.gov/36787503/ PubMed]
 +
*'''2018:''' Brown et al. [https://doi.org/10.1182/blood-2018-04-785980 How I treat infant leukemia] [https://pubmed.ncbi.nlm.nih.gov/30459160/ PubMed]
 +
 
 
===Children===
 
===Children===
 +
*'''2024:''' Bhat et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10862368/ How I treat pediatric venous thromboembolism in the DOAC era] [https://pubmed.ncbi.nlm.nih.gov/37390311/ PubMed]
 +
**'''2017:''' Young. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5813720/ How I treat pediatric venous thromboembolism] [https://pubmed.ncbi.nlm.nih.gov/28774877/ PubMed]
 +
*'''2023:''' Myers et al. [https://doi.org/10.1182/blood.2022016937 How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL] [https://pubmed.ncbi.nlm.nih.gov/36416729/ PubMed]
 +
*'''2023:''' Si Lim et al. [https://doi.org/10.1182/blood.2022016503 How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults] [https://pubmed.ncbi.nlm.nih.gov/37018730/ PubMed]
 +
*'''2021:''' Rubnitz & Kaspers. [https://doi.org/10.1182/blood.2021011694 How I treat pediatric acute myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/34115839/ PubMed]
 +
*'''2020:''' Hunger & Raetz. [https://doi.org/10.1182/blood.2019004043 How I treat relapsed acute lymphoblastic leukemia in the pediatric population] [https://pubmed.ncbi.nlm.nih.gov/32589723/ PubMed]
 +
*'''2020:''' Teachey & O'Connor [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6966932/ How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children] [https://pubmed.ncbi.nlm.nih.gov/31738819/ PubMed]
 +
*'''2019:''' Hijiya & Suttorp. [http://www.bloodjournal.org/content/133/22/2374.long How I treat chronic myeloid leukemia in children and adolescents]
 +
*'''2018:''' Gopal & Gross. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6053950/ How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa] [https://pubmed.ncbi.nlm.nih.gov/29769263/ PubMed]
 +
*'''2018:''' Locatelli & Strahm. [https://doi.org/10.1182/blood-2017-09-765214 How I treat myelodysplastic syndromes of childhood] [https://pubmed.ncbi.nlm.nih.gov/29438960/ PubMed]
 +
*'''2012:''' Locatelli et al. [https://doi.org/10.1182/blood-2012-02-265884 How I treat relapsed childhood acute lymphoblastic leukemia] [https://pubmed.ncbi.nlm.nih.gov/22896001/ PubMed]
  
 
===Adolescents and young adults (AYA)===
 
===Adolescents and young adults (AYA)===
 
*'''2023:''' Si Lim et al. [https://doi.org/10.1182/blood.2022016503 How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults] [https://pubmed.ncbi.nlm.nih.gov/37018730/ PubMed]
 
*'''2023:''' Si Lim et al. [https://doi.org/10.1182/blood.2022016503 How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults] [https://pubmed.ncbi.nlm.nih.gov/37018730/ PubMed]
 
*'''2019:''' Hijiya & Suttorp. [http://www.bloodjournal.org/content/133/22/2374.long How I treat chronic myeloid leukemia in children and adolescents]
 
*'''2019:''' Hijiya & Suttorp. [http://www.bloodjournal.org/content/133/22/2374.long How I treat chronic myeloid leukemia in children and adolescents]
 +
*'''2019:''' Young. [https://doi.org/10.1111/bjh.15942 How I treat children with haemophilia and inhibitors]
 +
*'''2018:''' Gopal & Gross. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6053950/ How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa] [https://pubmed.ncbi.nlm.nih.gov/29769263/ PubMed]
 
*'''2015:''' Curran & Stock. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4463735/ How I treat acute lymphoblastic leukemia in older adolescents and young adults] [https://pubmed.ncbi.nlm.nih.gov/25805810/ PubMed]
 
*'''2015:''' Curran & Stock. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4463735/ How I treat acute lymphoblastic leukemia in older adolescents and young adults] [https://pubmed.ncbi.nlm.nih.gov/25805810/ PubMed]
  
−
==Pregnancy==
+
===Older adults/Geriatric hematology===
 +
*'''2024:''' Facon et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10808246/ How I treat multiple myeloma in geriatric patients] [https://pubmed.ncbi.nlm.nih.gov/36693134/ PubMed]
 +
**'''2010:''' Mehta et al. [https://doi.org/10.1182/blood-2009-10-163329 How I treat elderly patients with myeloma] [https://pubmed.ncbi.nlm.nih.gov/20644120/ PubMed]
 +
*'''2024:''' Foy et al. [https://doi.org/10.1182/blood.2022017634 How I diagnose and treat thrombocytopenia in geriatric patients] [https://pubmed.ncbi.nlm.nih.gov/37956435/ PubMed]
 +
*'''2024:''' Oyedeji et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10808247/ How I treat anemia in older adults] [https://pubmed.ncbi.nlm.nih.gov/36827619/ PubMed]
 +
*'''2024:''' Poston & Kruse-Jarres [https://doi.org/10.1182/blood.2022018534 How I treat von Willebrand disorders in older adults] [https://pubmed.ncbi.nlm.nih.gov/37672774/ PubMed]
 +
*'''2023:''' Lugtenburg & Mutsaers [https://doi.org/10.1182/blood.2020008239 How I treat older patients with DLBCL in the frontline setting] [https://pubmed.ncbi.nlm.nih.gov/36413153/ PubMed]
 +
*'''2019:''' Chan & Eikelbloom. [https://doi.org/10.1182/blood-2019-01-846048 How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism]
 +
*'''2018:''' Thein & Howard. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6202910/ How I treat the older adult with sickle cell disease]
 +
*'''2014:''' Ossenkoppele & Löwenberg. [http://www.bloodjournal.org/content/125/5/767.long How I treat the older patient with acute myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/25515963/ PubMed]
 +
*'''2013:''' Gökbuget. [https://doi.org/10.1182/blood-2012-07-379016 How I treat older patients with ALL] [https://pubmed.ncbi.nlm.nih.gov/23673859/ PubMed]
 +
 
 +
==Complications of treatment==
 +
===Bleeding===
 +
*'''2017:''' Boonyawat et al. [https://doi.org/10.1182/blood-2017-07-797423 How I treat heavy menstrual bleeding associated with anticoagulants] [https://pubmed.ncbi.nlm.nih.gov/29092828/ PubMed]
 +
*'''2014:''' Schulman & Furie. [https://doi.org/10.1182/blood-2014-08-597781 How I treat poisoning with vitamin K antagonists] [https://pubmed.ncbi.nlm.nih.gov/25377783/ PubMed]
 +
*'''2014:''' Siegal et al. [https://doi.org/10.1182/blood-2013-09-529784 How I treat target-specific oral anticoagulant-associated bleeding] [https://pubmed.ncbi.nlm.nih.gov/24385535/ PubMed]
 +
 
 +
===Cardiovascular complications===
 +
*'''2022:''' Herrmann et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8914183/ How I treat cardiovascular complications in patients with lymphoid malignancies] [https://pubmed.ncbi.nlm.nih.gov/34752600/ PubMed]
 +
 
 +
===[[Immune effector cells toxicity management]]===
 +
*'''2023:''' Gutierrez et al. [https://doi.org/10.1182/blood.2022017579 How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy] [https://pubmed.ncbi.nlm.nih.gov/36827628/ PubMed]
 +
*'''2023:''' Jain et al. [https://doi.org/10.1182/blood.2022017414 How I treat refractory CRS and ICANS after CAR T-cell therapy] [https://pubmed.ncbi.nlm.nih.gov/36989488/ PubMed]
 +
*'''2023:''' Jain et al. [https://doi.org/10.1182/blood.2022017415 How I treat cytopenias after CAR T-cell therapy] [https://pubmed.ncbi.nlm.nih.gov/36800563/ PubMed]
 +
*'''2023:''' Santomasso et al. [https://doi.org/10.1182/blood.2022017604 How I treat unique and difficult-to-manage cases of CAR T-cell therapy-associated neurotoxicity] [https://pubmed.ncbi.nlm.nih.gov/36877916/ PubMed]
 +
*'''2020:''' Hill & Seo [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7441168/ How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies]
 +
===Infectious complications===
 +
*'''2023:''' Dadwal et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10163320/ How I prevent viral reactivation in high-risk patients] [https://pubmed.ncbi.nlm.nih.gov/36493341/ PubMed]
 +
*'''2022:''' El Chaer et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9249429/ How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies] [https://pubmed.ncbi.nlm.nih.gov/35776899/ PubMed]
 +
*'''2022:''' Law & Taplitz. [https://doi.org/10.1182/blood.2019003687 How I manage infection risk and prevention in patients with lymphoid cancer] [https://pubmed.ncbi.nlm.nih.gov/34748625/ PubMed]
 +
*'''2020:''' Hill & Seo. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7441168/ How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies]
 +
*'''2016:''' El Chaer et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5146744/ How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients] [https://pubmed.ncbi.nlm.nih.gov/27760756/ PubMed]
 +
*'''2016:''' Waghmare et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4891952/ How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation] [https://pubmed.ncbi.nlm.nih.gov/26968533/ PubMed]
 +
*'''2014:''' Nucci & Anaissie. [https://doi.org/10.1182/blood-2014-04-516211 How we treat invasive fungal diseases in patients with acute leukemia: the importance of an individualized approach] [https://pubmed.ncbi.nlm.nih.gov/25339358/ PubMed]
 +
 
 +
===Iron overload===
 +
*'''2012:''' Hoffbrand et al. [https://doi.org/10.1182/blood-2012-05-370098 How I treat transfusional iron overload] [https://pubmed.ncbi.nlm.nih.gov/22919029/ PubMed]
 +
 
 +
===Medication toxicities===
 +
*'''2017:''' Delforge & Ludwig. [https://doi.org/10.1182/blood-2017-01-725705 How I manage the toxicities of myeloma drugs] [https://pubmed.ncbi.nlm.nih.gov/28275090/ PubMed]
 +
 
 +
===Neurologic medications===
 +
*'''2022:''' Nayak & Batchelor. [https://doi.org/10.1182/blood.2019003690 How I treat neurologic complications in patients with lymphoid cancer] [https://pubmed.ncbi.nlm.nih.gov/34479368/ PubMed]
 +
 
 +
==Genetic risk==
 +
*'''2023:''' Hamilton et al. [https://doi.org/10.1182/blood.2022017379 How I communicate with patients and families about germ line genetic information] [https://pubmed.ncbi.nlm.nih.gov/37023453/ PubMed]
 +
*'''2016:''' University of Chicago Hematopoietic Malignancies Cancer Risk Team [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5813725/ How I diagnose and manage individuals at risk for inherited myeloid malignancies] [https://pubmed.ncbi.nlm.nih.gov/27471235/ PubMed]
 +
 
 +
==Gynecologic considerations==
 +
===Menstruation===
 +
*'''2017:''' Boonyawat et al. [https://doi.org/10.1182/blood-2017-07-797423 How I treat heavy menstrual bleeding associated with anticoagulants] [https://pubmed.ncbi.nlm.nih.gov/29092828/ PubMed]
 +
===Pregnancy===
 +
*'''2024:''' Branch & Lim [https://doi.org/10.1182/blood.2023020727 How I diagnose and treat antiphospholipid syndrome in pregnancy] [https://pubmed.ncbi.nlm.nih.gov/38145574/ PubMed]
 +
*'''2024:''' Fogerty & Kuter [https://doi.org/10.1182/blood.2023020726 How I treat thrombocytopenia in pregnancy] [https://pubmed.ncbi.nlm.nih.gov/37992219/ PubMed]
 +
**'''2012:''' Gernsheimer et al. [https://doi.org/10.1182/blood-2012-08-448944 How I treat thrombocytopenia in pregnancy] [https://pubmed.ncbi.nlm.nih.gov/23149846/ PubMed]
 +
*'''2024:''' James & Strouse [https://doi.org/10.1182/blood.2023020728 How I treat sickle cell disease in pregnancy] [https://pubmed.ncbi.nlm.nih.gov/37979134/ PubMed]
 +
*'''2024:''' Robinson et al. [https://doi.org/10.1182/blood.2023020729 How I treat myeloproliferative neoplasms in pregnancy] [https://pubmed.ncbi.nlm.nih.gov/38145575/ PubMed]
 +
*'''2022:''' Fiore et al. [https://doi.org/10.1182/blood.2021011595 How I manage pregnancy in women with Glanzmann thrombasthenia]
 +
*'''2020:''' Dunleavy & McLintock. [https://doi.org/10.1182/blood.2019000961 How I treat lymphoma in pregnancy]
 
*'''2020:''' Ferrari & Peyvandi. [https://doi.org/10.1182/blood.2019000962 How I treat thrombotic thrombocytopenic purpura in pregnancy]
 
*'''2020:''' Ferrari & Peyvandi. [https://doi.org/10.1182/blood.2019000962 How I treat thrombotic thrombocytopenic purpura in pregnancy]
 
*'''2020:''' Leebeek et al. [https://doi.org/10.1182/blood.2019000964 How I manage pregnancy in carriers of hemophilia and patients with von Willebrand disease]
 
*'''2020:''' Leebeek et al. [https://doi.org/10.1182/blood.2019000964 How I manage pregnancy in carriers of hemophilia and patients with von Willebrand disease]
 
*'''2020:''' Middeldorp & Ganzevoort. [https://doi.org/10.1182/blood.2019000963 How I treat venous thromboembolism in pregnancy]
 
*'''2020:''' Middeldorp & Ganzevoort. [https://doi.org/10.1182/blood.2019000963 How I treat venous thromboembolism in pregnancy]
 +
*'''2016:''' Achebe & Gafter-Gvili. [https://doi.org/10.1182/blood-2016-08-672246 How I treat anemia in pregnancy: iron, cobalamin, and folate] [https://pubmed.ncbi.nlm.nih.gov/28034892/ PubMed]
 +
*'''2013:''' Milojkovic & Apperley. [https://doi.org/10.1182/blood-2013-08-283580 How I treat leukemia during pregnancy] [https://pubmed.ncbi.nlm.nih.gov/24269956/ PubMed]
 +
 +
===Postpartum period===
 +
*'''2015:''' Pavord & Maybury. [https://doi.org/10.1182/blood-2014-10-512608 How I treat postpartum hemorrhage] [https://pubmed.ncbi.nlm.nih.gov/25769619/ PubMed]
 +
 +
==Hospitalization==
 +
*'''2023:''' Akpan & Hunt. [https://doi.org/10.1182/blood.2021014835 How I approach the prevention and treatment of thrombotic complications in hospitalized patients] [https://pubmed.ncbi.nlm.nih.gov/37339577/ PubMed]
 +
*'''2023:''' Samuelson Bannow & Konkle. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10562531/ How I approach bleeding in hospitalized patients] [https://pubmed.ncbi.nlm.nih.gov/36652635/ PubMed]
 +
*'''2023:''' Zon & Berliner. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc10562528/ How I manage inpatient consultations for quantitative neutrophil abnormalities in adults] [https://pubmed.ncbi.nlm.nih.gov/36279420/ PubMed]
 +
*'''2012:''' Dobromirski & Cohen. [https://doi.org/10.1182/blood-2012-03-378901 How I manage venous thromboembolism risk in hospitalized medical patients] [https://pubmed.ncbi.nlm.nih.gov/22705598/ PubMed]
  
 +
==Regional considerations==
 +
*'''2018:''' Gopal & Gross. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6053950/ How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa] [https://pubmed.ncbi.nlm.nih.gov/29769263/ PubMed]
 +
 +
==Surgical considerations==
 +
*'''2020:''' Shander et al. [https://doi.org/10.1182/blood.2019003945 How I treat anemia in the perisurgical setting]
 +
*'''2012:''' Spyropoulos & Douketis. [https://doi.org/10.1182/blood-2012-06-415943 How I treat anticoagulated patients undergoing an elective procedure or surgery] [https://pubmed.ncbi.nlm.nih.gov/22932800/ PubMed]
 +
 +
==Transplantation==
 +
===[[Allogeneic HSCT]]===
 +
*'''2024:''' Mina et al. [https://doi.org/10.1182/blood.2023023005 How I reduce and treat posttransplant relapse of MDS] [https://pubmed.ncbi.nlm.nih.gov/38306658/ PubMed]
 +
*'''2023:''' DeFilipp & Chen. [https://doi.org/10.1182/blood.2021012412 How I treat with maintenance therapy after allogeneic HCT] [https://pubmed.ncbi.nlm.nih.gov/35231083/ PubMed]
 +
*'''2021:''' Burns & Morris. [https://doi.org/10.1182/blood.2020008187 How I use allogeneic HSCT for adults with inborn errors of immunity] [https://pubmed.ncbi.nlm.nih.gov/34077952/ PubMed]
 +
*'''2020:''' Puerta-Alcalde et al. [https://doi.org/10.1182/blood.2020005884 How I perform hematopoietic stem cell transplantation on patients with a history of invasive fungal disease] [https://pubmed.ncbi.nlm.nih.gov/33301030/ PubMed]
 +
*'''2019:''' McCurdy & Luznik. [https://doi.org/10.1182/blood.2019001323 How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide] [https://pubmed.ncbi.nlm.nih.gov/31751485/ PubMed]
 +
*'''2018:''' Gribben. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6034643/ How and when I do allogeneic transplant in CLL] [https://pubmed.ncbi.nlm.nih.gov/29752258/ PubMed]
 +
*'''2017:''' Alvarnas et al. [https://doi.org/10.1182/blood-2017-04-551606 How I treat patients with HIV-related hematological malignancies using hematopoietic cell transplantation] [https://pubmed.ncbi.nlm.nih.gov/28882882/ PubMed]
 +
*'''2017:''' Williams. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5270387/ How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation] [https://pubmed.ncbi.nlm.nih.gov/27856461/ PubMed]
 +
*'''2016:''' El Chaer et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5146744/ How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients] [https://pubmed.ncbi.nlm.nih.gov/27760756/ PubMed]
 +
*'''2012:''' Wingard et al. [https://doi.org/10.1182/blood-2012-02-378976 How I manage pulmonary nodular lesions and nodular infiltrates in patients with hematologic malignancies or undergoing hematopoietic cell transplantation] [https://pubmed.ncbi.nlm.nih.gov/22692506/ PubMed]
 +
 +
===[[Autologous HSCT]]===
 +
*'''2014:''' Gertz & Dingli. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4126328/ How we manage autologous stem cell transplantation for patients with multiple myeloma] [https://pubmed.ncbi.nlm.nih.gov/24973360/ PubMed]
 +
 +
===[[Graft versus host disease|Graft versus host disease (GVHD)]]===
 +
*'''2023:''' Cooper & Abkowitz. [https://doi.org/10.1182/blood.2022015954 How I diagnose and treat acute graft-versus-host disease after solid organ transplantation]
 +
*'''2023:''' Rimando et al. [https://doi.org/10.1182/blood.2021015129 How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond]
 +
*'''2020:''' Martin. [https://doi.org/10.1182/blood.2019000960 How I treat steroid-refractory acute graft-versus-host disease] [https://pubmed.ncbi.nlm.nih.gov/32202630/ PubMed]
 +
*'''2019:''' Sarantopoulos et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6418480/ How I treat refractory chronic graft-versus-host disease]
 +
*'''2016:''' McDonald. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4807421/ How I treat acute graft-versus-host disease of the gastrointestinal tract and the liver] [https://pubmed.ncbi.nlm.nih.gov/26729898/ PubMed]
 +
*'''2014:''' Flowers & Martin. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4304105/ How we treat chronic graft-versus-host disease]
 +
*'''2012:''' Treister et al. [https://doi.org/10.1182/blood-2012-05-393389 How we treat oral chronic graft-versus-host disease] [https://pubmed.ncbi.nlm.nih.gov/22898605/ PubMed]
 +
*'''2007:''' Deeg. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc1885485/ How I treat refractory acute GVHD] [https://pubmed.ncbi.nlm.nih.gov/17234737/ PubMed]
 +
 +
=Miscellaneous=
 +
==Acute respiratory failure==
 +
*'''2024:''' Azoulay et al. [https://doi.org/10.1182/blood.2023021414 How I manage acute respiratory failure in patients with hematological malignancies] [https://pubmed.ncbi.nlm.nih.gov/38232056/ PubMed]
 +
 +
==Atrial fibrillation==
 +
*'''2016:''' Steinberg. [https://doi.org/10.1182/blood-2016-07-693614 How I use anticoagulation in atrial fibrillation] [https://pubmed.ncbi.nlm.nih.gov/27780804/ PubMed]
 +
 +
==Cryoglobulinemia==
 +
*'''2016:''' Muchtar et al. [https://doi.org/10.1182/blood-2016-09-719773 How I treat cryoglobulinemia] [https://pubmed.ncbi.nlm.nih.gov/27799164/ PubMed]
 
[[Category:Hematology reference pages]]
 
[[Category:Hematology reference pages]]
 
[[Category:Evidence-based oncology]]
 
[[Category:Evidence-based oncology]]
 +
==Immunodeficiency==
 +
===Common variable immune deficiency (CVID)===
 +
*'''2010:''' Cunningham-Rundles. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc2904582/ How I treat common variable immune deficiency] [https://pubmed.ncbi.nlm.nih.gov/20332369/ PubMed]
 +
===Severe combined immunodeficiency (SCID)===
 +
*'''2013:''' Gaspar et al. [https://doi.org/10.1182/blood-2013-02-380105 How I treat severe combined immunodeficiency] [https://pubmed.ncbi.nlm.nih.gov/24113871/ PubMed]
 +
==Priapism==
 +
*'''2015:''' Anele et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4458797/ How I treat priapism] [https://pubmed.ncbi.nlm.nih.gov/25810489/ PubMed]
 +
==Protoporphyria==
 +
*'''2023:''' Karp Leaf & Dickey. [https://doi.org/10.1182/blood.2022018688 How I treat erythropoietic protoporphyria and X-linked protoporphyria] [https://pubmed.ncbi.nlm.nih.gov/36898083/ PubMed]
 +
 +
==T-cell chronic active Epstein-Barr virus disease (CAEBV)==
 +
*'''2018:''' Bollard & Cohen. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6024635/ How I treat T-cell chronic active Epstein-Barr virus disease] [https://pubmed.ncbi.nlm.nih.gov/29712633/ PubMed]

Revision as of 11:58, 25 June 2024

Back to Top

The "How I Treat" series has been published by Blood for several decades and covers a wide variety of topics in malignant and classical hematology. While these articles are not considered to be formal guidelines, they are considered highly reputable sources of expert opinion. They cover topics ranging from commonly encountered hematologic conditions with a large evidence base, to very rare conditions with only case reports to guide treatment. The purpose of this page is to consolidate the links to all known published How I Treat articles. While the vast majority of these are published in Blood, there are a few exceptions.

In the first two sections (malignant hematology and classical hematology), articles are presented by condition, in reverse chronological order. In the third section, articles are gathered under "special considerations" such as pregnancy and hematologic disease. The fourth section contains miscellaneous topics that do not easily fit into the above categories. Given the rapid change in evidence in many areas of hematology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.

Malignant hematology

Acute leukemias

Mixed-phenotype acute leukemia (MPAL)

Myeloid neoplasms

Acute lymphoblastic leukemia (ALL)

Acute myeloid leukemia (AML)

Acute promyelocytic leukemia (APL)

Chronic myeloid leukemia (CML)

Chronic myelomonocytic leukemia (CMML)

Hypereosinophilic syndrome (HES)

Myelodysplastic syndrome (MDS)

Myeloproliferative neoplasms (MPNs)

Essential thrombocythemia (ET)

Myelofibrosis (MF)

Polycythemia vera (PV)

Systemic mastocytosis

Lymphoid neoplasms

Adult T-cell leukemia-lymphoma (ATLL)

Anaplastic large cell lymphoma

Burkitt lymphoma (BL)

Castleman disease

Chronic lymphocytic leukemia (CLL/SLL)

Classical Hodgkin lymphoma (cHL)

CNS lymphoma

Cutaneous T-cell lymphoma (CTCL)

Diffuse large B-cell lymphoma (DLBCL)

Follicular lymphoma (FL)

High-grade B-cell lymphoma (HGBL)

HIV-associated lymphoma

Large granular lymphocytic leukemia (T-LGL)

Mantle cell lymphoma (MCL)

NK- and T-cell lymphoma (NKTCL)

Nodular lymphocyte-predominant Hodgkin lymphoma (NLP-HL)

Peripheral T-cell lymphoma (PTCL)

Post-transplant lymphoproliferative disorder (PTLD)

Primary mediastinal B-cell lymphoma (PMBCL)

Prolymphocytic leukemia (T-PLL)

Splenic lymphoma

Transformed lymphoma

Waldenström macroglobulinemia (WM)

Plasma cell dyscrasias

Light-chain (AL) amyloidosis

MGUS

Multiple myeloma (MM)

Plasma cell leukemia (PCL)

Smoldering multiple myeloma (SMM)

Histiocytic disorders

Hemophagocytic lymphohistiocytosis (HLH)

Langerhans cell histiocytosis (LCH)

Classical hematology

Hemostasis and thrombosis

Acquired thrombotic thrombocytopenic purpura (aTTP)

Antiphospholipid antibody syndrome (APS)

Arterial thromboembolism (ATE)

Disseminated intravascular coagulation (DIC)

Hemophilia

Heparin-induced thrombocytopenia (HIT)

Thrombotic microangiopathy (TMA)

Venous thromboembolism (VTE)

von Willebrand disease (vWD)

Cytopenias

Acquired pure red cell aplasia

Anemia

Aplastic anemia

Autoimmune cytopenia

Immune thrombocytopenia (ITP)

Neutropenia & leukopenia

Thrombocytopenia and platelet dysfunction

WHIM syndrome

Hemoglobinopathies

Beta thalassemia

Sickle cell disease

Hemolytic disorders

Cold agglutinin disease (CAD)

Atypical hemolytic uremic syndrome (aHUS)

Paroxysmal nocturnal hemoglobinuria (PNH)

Warm autoimmune hemolytic anemia (WAIHA)

Special considerations

Age-based recommendations

The majority of How I Treat articles focus on "standard" adults; below, articles that focus on other age populations are concatenated.

Neonates

Children

Adolescents and young adults (AYA)

Older adults/Geriatric hematology

Complications of treatment

Bleeding

Cardiovascular complications

Immune effector cells toxicity management

Infectious complications

Iron overload

Medication toxicities

Neurologic medications

Genetic risk

Gynecologic considerations

Menstruation

Pregnancy

Postpartum period

Hospitalization

Regional considerations

Surgical considerations

Transplantation

Allogeneic HSCT

Autologous HSCT

Graft versus host disease (GVHD)

Miscellaneous

Acute respiratory failure

Atrial fibrillation

Cryoglobulinemia

Immunodeficiency

Common variable immune deficiency (CVID)

Severe combined immunodeficiency (SCID)

Priapism

Protoporphyria

T-cell chronic active Epstein-Barr virus disease (CAEBV)

Retrieved from "https://hemonc.org/w/index.php?title=How_I_Treat&oldid=86656"